Clinical Trial Details
— Status: Recruiting
Administrative data
| NCT number |
NCT04800497 |
| Other study ID # |
FINDINGBIOREC |
| Secondary ID |
|
| Status |
Recruiting |
| Phase |
|
| First received |
|
| Last updated |
|
| Start date |
February 7, 2019 |
| Est. completion date |
February 7, 2026 |
Study information
| Verified date |
January 2024 |
| Source |
University of Milano Bicocca |
| Contact |
Simone Famularo |
| Phone |
+39 3296533353 |
| Email |
simone.famularo[@]gmail.com |
| Is FDA regulated |
No |
| Health authority |
|
| Study type |
Observational
|
Clinical Trial Summary
Hepatocellular carcinoma (HCC) recurs in up to 60% of patients who undergo resection.
Circulating tumor cells (CTC) have been advocated as promotors of the recurrence. However,
their role as prognostic markers in the surgical setting is unclear. The aim of the present
study has been to assess the association between CTC from peripheral blood samples and the
risk of recurrence after surgery.
Patients with a first diagnosis of HCC, no previous treatment for this condition, no other
oncological history, and BCLC stage 0-A-B will be enrolled in 2 centers. Patients will
undergo to serial liquid biopsies (i.e., a 15ml peripheral blood sample on each time point)
at day 0-30-90-180-365 after surgery. After isolation of peripheral blood mononucleate cells,
CTC will be detected by FACSymphony™ and subsequently the following markers will be
identified: EpCAM, N-cadherin (N-cad) and CD90. Epithelial-mesenchymal transition (EMT) will
be analyzed by an index estimated as the ratio between the number of EpCAM+/N-cad- and
EpCAM+/N-cad+ cells (EMT Index). Patients will be divided according to the recurrence status.
Description:
Liquid biopsy may allow a better stratification of patients according to their estimated
prognosis. As well in other tumors (e.g. breast cancer), molecular characterization is
permitting not only to better understand the pathological pathways which lead tumorigenesis
and progression, but also to drive specific treatments tailored on the specificity of the
patient disease. Liquid biopsy is very easy and cheap to perform, since it consist in a
simple venous blood sample which will be investigated by cells sorter to identify specific
populations of cells.
In hepatocellular carcinoma is common to assist on an elevated recurrence rate: patients who
have been treated with a curative intent, in 70% of cases relapse. In these cases, patients
often had an underlying inflammatory liver disease, as cirrhosis, which may drive the relapse
as an oncogenetic factor. Cirrhosis is a well-know risk factor for developing hepatocellular
carcinoma in general. Because of this, in clinical practice is almost difficult to
distinguish if the new nodule we have diagnosed should be considered as a real recurrence of
the first treated tumor, or a de-novo occurrence linked to the unchanged underlying
tumorigenesis boost, which may be effectively cured only after liver transplantation. Several
retrospective studies already demonstrated the advantage, in terms of disease-free-survival
and overall-survival, of a de-novo occurrence in respect to a real metastatic presentation.
However, no one has reached any specific clinical or morphological markers to distinguish
between these two conditions. Characterization of the nature of the recurrent nodule has been
obtained only by genetic and molecular evaluation of the tumors heterogeneity. Nevertheless,
this characterization nowadays is possible only with research intent, and on histological
specimen, which could be provided only after an eventual decision of redo-surgery to treat
the considered recurrence. Indication on how to treat HCC recurrence after surgery still
lacks. Our hypothesis is founded on the "seed and oil" theory, which is basically founded on
the evidence of the presence of circulating tumor cells (CTCs) in the blood stream. These
cells may be spread from the original tumors as an hallmark of advance cancer, which has
already developed the invasiveness characteristic. It is our opinion that tumors in an early
stage do not release, or not in the same rate or quality, CTCs in the bloodstream as advanced
tumor does. We considered an advanced tumor the one which may has already microvascular
invasion and/or satellitosis, which may be the histological signs of an advanced and already
systemic stage. Patients with CTCs identified at the liquid biopsy may be associated with a
worsen prognosis, accounting for an increased rate of early recurrence and overall
recurrence, even in case of transplantation. In addition, the "seed and oil" theory,
associated with the "rehoming theory" may justified, from a bio-oncological point of view,
the cases of recurrence in the transplant setting, when the whole organ, and the relative
oncogenetic risk factors, is treated by substitution. Finally, from a pathophysiological
point of view, we want to demonstrate that recurrent intra-hepatic nodules (IM) are due to
circulating tumour cells'seeding, permitting a better understanding of carcinogenesis in
those tumours.
- Primary objective: to evaluate the association between variation in CTCs - determined in
blood samples - and overall survival and disease-free-survival in HCC patients before
and after surgery (either resection and transplant).
- Secondary objective: to evaluate if the positive identification of CTCs in blood samples
is associated with the intra-hepatic metastatic pattern of recurrence in either resected
patients and transplanted one.
- Tertiary objective: to evaluate and to monitor the role of different clinical,
biochemical, radiological and histopathological variables in determining the recurrence
after surgery and their eventual relationship with the presence and rate of CTCs
Patients enrollment will be assessed by the surgical divisions of this study, usually
during the outpatient clinic visit before the surgical operation. In that moment
patients will be candidate for this study, and, if they accept to participate,
researchers will acquire the written consent. Enrolled patients will be codified by an
alpha-numeric number to preserve the identity. Researchers who will be employed in the
laboratory where the CTCs will be analyzed will not be able to trace the owner of the
sample, and they will not have the access to the clinical data (blind analysis).
Before surgery for each patient liquid biopsy from peripheral blood will be collected (in the
same time of routine blood analysis). Samples will be used to analyze CTCs rate and type by
FACSARIA III (BD bioscience). During surgery, a fresh slice of the tumor and near health
liver will be collected by an expert pathologist, who will use section(s) for the usual
histological evaluation as provided by the best clinical practice and international
guidelines. The remaining sections will be maintained on ice during shipment to the
laboratory unit. Researchers will perform alive hepatic cells isolation and storage under
sterile conditions. Then, hepatic cells will be analyzed with FACSARIA III and used for
further in-vitro experiments.
Liquid biopsy will be performed again at 30th post-operative day during the first outpatient
visit, and then every six months, in accordance and in parallel with the local follow-up
protocols. Liquid biopsy performed during follow-up will be managed as the pre-operative one,
during the normal tests provided for clinical purpose. Follow-up will be closed at 30 months.
All operations will be performed by surgeons with large experience in liver surgery. The
resection technique will be at surgeon preference, according to local protocol, good clinical
practise and national guidelines. All surgeons adopted the same criteria to select the
surgical strategy: baseline variables of liver function, tumour location and diameter, and
number of nodules. Restaging Ultrasonography (US) will be performed intra-operatively for
each patient. After tumor removal, a pathologist involved in this study will sample the tumor
to obtain a fresh-frozen section of the tumor, with the related healthy liver tissue, to
store it for further analysis. This sample should be performed in accordance with
international guidelines and local ethical agreement, and it must always guarantee the
correct material to perform the histological diagnosis. If the tissue removed from the
patient enrolled in this study does not allow to perform the sample for the study without
affecting the optimal histological diagnosis, the patient will be excluded from the study and
no sampling will be executed.
For all patients 20 mL fasting blood sample will be collected in a sterile vacuum tube. The
collection will be done in the same time of routine preoperative blood samples or planned
follow-up controls, since no others invasive procedure should be provided to patients since
their enrollment in the study. The blood sample will be stored at 4°C and handled within 6
hours. Then, 5 mL will be centrifuged at 3000 rpm for 10 minutes at 4°C, the plasma phase
will be collected and aliquoted in 1.5 mL sterile tubes and stored at -80°C until use or
shipment. Then, we will isolate peripheral blood mononucleate cells (PBMC) through Ficoll
gradient from the remaining 15 mL. After isolation, live PBMC will be frozen in standard
media 20% Fetal Bovin Serum (FBS) 10% Dymethil Sulfoxide (DMSO) and stored in liquid nitrogen
until use.
For all patient liver tissue sample will be collected and tumor (T) portion will be separated
from peritumor (PT) portion. From T and PT tissue will be isolated consequentially Human
Hepatocytes (HC), Kupffer cells (KC), Liver Sinusoidal Endothelial Cells (LSEC) and Human
Stellate Cells (HSC) under sterile conditions. Briefly, liver tissue will be placed in a
Petri dish and cut with sterile scalpel. Then, cut liver will be incubated in a 50 mL tube
with collagenase P (1mg/mL) at 37°C for 45 minutes. After incubation, collagenase P will be
inactivated adding 20% FBS Hank's Balance Salt Solution (HBSS) and cell suspension will be
centrifuged 50g 5 minutes at 4°C. The supernatant, containing liver non-parenchymal cells
(NPC), will be collected in a new 50 mL tube and pellet will be washed with Phosphate Buffer
Solution (PBS). HC and NPC will be frozen in standard media 20% FBS 10% DMSO and stored in
liquid nitrogen until use.
A fragment of T and PT will be stored in RNAlater solution at -80°C. For CTC identification
PBMC will be thawed, resuspended in standard media and sorted with FACSARIA III (BD
bioscience) through EpCAM+, CD47+, CD133+. The percentage of single positive cells (EpCAM+,
CD47+ and CD133+) and triple positive cells (EpCAM/CD47/CD133+++) will be evaluated and the
total CTC number will be calculated. CTC will be tested for their replicative and invasive
capacity. Using cell proliferation and invasion assay we will evaluate CTC doubling time
(time needed for the cells to double in number), growth rate (gr=[ln(N(t)/N(0)]/t; N(t)= the
number of cells at time t, N(0)= the number of cells at time 0, t= time) and invasion rate.
After CTC characterization we will analyse HC and NPC, using the positive markers previously
described, in order to evaluate the exact CTC hepatic derivation.
The biological material will be shipped by expert private transport and stored to the
laboratory in "Università degli Studi del Piemonte Orientale".
The recurrence patterns will be evaluated as follow. Local recurrence will be defined as a
recurrence on the same liver segment in case of Parenchyma Sparing Resection, or on the
surgical hedge of the nearest segments in case of Anatomic Resection. Thus, it will be
evaluated the number of recurrent nodules (single versus multiple), the location of
recurrence (intrahepatic versus extrahepatic or both), the size of the main recurrent nodule
and the liver segment. All this evaluations on recurrence will be made by CT scan or MRI scan
during follow-up, as the local follow-up protocols provide.
All the patients will be followed using a local protocol including measurement of serum α-FP,
total bilirubin, GGT, ALP, Albumine, INR, blood count, electrolyte count, ultrasound,
contrast Computed Tomography (CT) or magnetic Resonance Imaging (MRI) and office visits.
Patients usually are checked every 3 months during the first postoperative year and every 6
months thereafter. When the recurrence occurred, the cases are discussed in a
multidisciplinary setting, involving radiologist, hepatologist, surgeon, interventional
radiologist, radiotherapist and oncologist. Overall-Survival (OS) is defined as time interval
(in months) from surgery to patient death. Data will be censored in case of loosed patient at
the follow-up screening. Disease-Free Survival (DFS) is defined as time interval (in months)
from surgery to recurrence or death. In case of no recurrence, data will be censored at the
date of the last available follow-up. Tumor-Specific-Survival (TSS) is defined as the time
interval in months between surgery and tumor-related death.
